Clozapine: The commitment to patient safety

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 12, 1999, Pages 39-42

  Alphs, Larry D ^a   Anand, Ravi ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE;

AGRANULOCYTOSIS; ALGORITHM; BLOOD ANALYSIS; BLOOD TOXICITY; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FATALITY; HUMAN; LEUKOCYTE; PATIENT MONITORING; PRIORITY JOURNAL; REGISTER; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA;

AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG MONITORING; DRUG RESISTANCE; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0032978563     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
2. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712
3. McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999;60(suppl 12):24-29
4. Ranjan R, Meltzer HY. Acute and long term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996;40: 253-258
5. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-611
6. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
7. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
8. Peacock L, Solgaard T, Lublin H, et al. Clozapine versus typical antipsychotics: a retro-and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996;124:188-196
9. Kirkegaard A, Hammershoj E, Ostergard P. Evaluation of side effects due to clozapine in long-term treatment of psychosis. Arzneimittelforschung 1982;31:465-468
10. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99(suppl):S18-S27
11. Dev VJ, Krupp P. Adverse event profile and safety of clozapine. Rev Contemp Pharmacotherap 1995;6:197-208
12. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 1977;11:199-201
13. Lieberman JA, Johns CA, Kane JM, et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271-277
14. Idanpaan-Heikkila J, Alhava E, Olkinuora M, et al. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977;11:193-198
15. Amsler HA, Teerenhovi L, Barth E, et al. Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241-248
16. de la Chapelle A, Kari C, Nurminen M, et al. Clozapine-induced agranulocytosis: a genetic and epidemiologic study. Hum Genet 1977;37:183-194
17. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 1992;160(suppl 17):38-40
18. Clozaril [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 1998
19. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
20. Honigfeld G. The Clozapine National Registry System: forty years of risk management. J Clin Psychiatry Monogr 1996;14(2):29-32
21. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(suppl 3):3-7
22. Honigfeld G. Effects of the Clozapine National Registry System on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996;47:52-56